• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Bolno Paul

    6/15/23 4:39:34 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SQZ alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    BOLNO PAUL

    (Last) (First) (Middle)
    200 ARSENAL YARDS BLVD, SUITE 210

    (Street)
    WATERTOWN MA 02472

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    SQZ Biotechnologies Co [ SQZ ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/14/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $0.539 06/14/2023 A 39,875 (1) 06/13/2033 Common Stock 39,875 $0.00 39,875 D
    Explanation of Responses:
    1. The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.
    Remarks:
    /s/ Lawrence Knopf as Attorney in Fact for Paul Bolno 06/15/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SQZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SQZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SQZ
    Leadership Updates

    Live Leadership Updates

    See more
    • SQZ Biotechnologies Announces Leadership Transition

      Chief Scientific Officer, Howard Bernstein, M.D., Ph.D., to Become Member of the Company's Board of Directors, Effective October 31, 2022 CSO Responsibilities to be Shared Among Ipsita Roymoulik, Ph.D., Scott Loughhead, Ph.D., and Maisam Dadgar as Senior Leaders of Chemistry, Manufacturing and Controls; Translational Research; and Engineering SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Howard Bernstein, M.D., Ph.D., has been appointed to the company's board of directors, effective October 31, 2022. Dr. Bernstein has served as the company's Chief Scientific Officer since July 2015, a

      9/6/22 4:30:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer

      Experienced Biotech Leader and Capital Markets Professional Elevated to Chief Financial Officer from Chief Business Officer Role Appointment Effective July 11, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Micah Zajic, as the company's Chief Financial Officer, effective immediately. Mr. Zajic has served as the company's Chief Business Officer since October 2020 and brings nearly 20 years of biotechnology and capital markets experience to the role. As CFO, Mr. Zajic will continue to report to the CEO and will lead the company's finance and accounting, business development,

      7/11/22 4:45:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer

      Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease Appointment Effective June 1st, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical Officer. Dr. Warren will report to the CEO and lead the company's clinical development, clinical operations, translational medicine, and regulatory affairs functions. Marshelle has tremendous experience in cell-based therapeutic development and will provide complementary expertise as we seek to rapidly advan

      5/31/22 4:45:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Vink Patrick V.J.J.

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:48:26 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Srivastava Sapna

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:47:28 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Schulman Amy W

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:46:40 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Financials

    Live finance-specific insights

    See more
    • SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient

      Patient's Clinical, Radiographic and Histologic Results Support Potential Impact of SQZ Investigational Therapeutic  Patient Demonstrated Symptomatic Improvement Radiographic Response Observed in Target Lesion Tumor Conversion from Desert to Inflamed Phenotype with 8-Fold Increase in CD8 T Cell Tumor Infiltration and 50-Fold Increase in Tumor PD-L1 Expression Interim Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and Investigational Therapy was Generally Well Tolerated  Company to Host Conference Call Today at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented

      12/9/21 6:10:00 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose

      Interim SQZ-PBMC-HPV Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and that Therapy was Generally Well Tolerated Oral Presentation at ESMO Immuno-Oncology Congress on December 9 to Focus on Highest-Dose Monotherapy Cohort of SQZ™ APC Candidate Company to Host Conference Call on December 9 at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced interim results from the highest-dose monotherapy cohort of its ongoing Phase 1/2 clinical trial of SQZ-PBMC-HPV, an investigational cell therapy being evaluated in certain patients with advanced or metastatic Human Papillomavirus

      12/2/21 6:15:00 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split

      Company Received Notice Regarding NYSE Continued Listing Standards Section 802.01B SQZ Biotechnologies Company (NYSE:SQZ) (the "Company" or "SQZ"), focused on unlocking the full potential of cell therapies, today announced that its Board of Directors (the "Board") has approved a 1-for-10 reverse stock split ("reverse split") of its common stock, par value $0.001 per share ("Common Stock"), that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time (the "Effective Date"). The Company's common stock is expected to begin trading on a split-adjusted basis on the New York Stock Exchange ("NYSE") on July 7, 2023, under the existing symbol "SQZ" and new CUSIP number

      6/15/23 4:30:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates

      Phase 1 SQZ-AAC-HPV-101 Clinical Trial Resumed Following the Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023 SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent portfolio updates. "The confirmed complete response in our first patient in the AAC trial has brought enthusiasm to our trial sites, and we are encouraged by the positive momentum for e

      5/10/23 4:45:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

      A confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial Following review and recommendation by the Study Safety Committee, the Company is advancing SQZ-AAC-HPV-101 trial to the highest-dose cohort Strong enrollment rates; Anticipate initial clinical data from the highest-dose cohort in the fourth quarter of 2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The co

      3/22/23 4:50:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

      SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

      2/13/24 5:13:06 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

      SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

      2/9/24 5:10:57 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

      SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

      2/14/23 2:25:08 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    SEC Filings

    See more
    • SEC Form DEFM14A filed by SQZ Biotechnologies Company

      DEFM14A - SQZ Biotechnologies Co (0001604477) (Filer)

      1/23/24 4:31:01 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form PREM14A filed by SQZ Biotechnologies Company

      PREM14A - SQZ Biotechnologies Co (0001604477) (Filer)

      1/12/24 8:57:36 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 15-12G filed by SQZ Biotechnologies Company

      15-12G - SQZ Biotechnologies Co (0001604477) (Filer)

      1/4/24 4:15:33 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care